Proteins.1
Proteins.1 provides an enzyme‑free, physics‑based multi‑omics platform that simultaneously detects DNA, RNA, and proteins with ultra‑high sensitivity in a single assay. By eliminating amplification steps, the technology reduces assay time and variability, delivering quantitative results that integrate into standard lab workflows for faster biomarker validation and drug target discovery.
- Biotechnology
Funding
Raised to date
€4.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $5.1Macross 1 round
BFCVV€4.7M · Pre-Seed
Announced Apr 2026
Disclosed cumulative: $5.1M
Founders
Founder details are not available yet.
Product
Problem
Current protein detection methods rely on enzymes and amplification steps, which limit sensitivity, increase assay complexity, and delay the identification of low‑abundance biomarkers. This hampers early disease diagnosis, slows biomarker research, and extends drug‑discovery timelines.
Solution
Proteins.1 offers a physics‑based, enzyme‑free multi‑omics platform that detects DNA, RNA, and proteins in a single assay with ultra‑high sensitivity. By eliminating enzymatic reactions, the technology reduces assay time and variability while enabling the measurement of molecular signals that are otherwise undetectable. The platform generates quantitative readouts that can be integrated into existing laboratory workflows, supporting earlier diagnostic decisions, accelerated biomarker validation, and faster drug‑target identification.
Target Audience
Primary customers are pharmaceutical and biotech R&D teams, clinical diagnostic laboratories, and academic researchers focused on biomarker discovery and multi‑omics studies.
Features
- Enzyme‑free detection chemistry that avoids amplification bias and reduces assay steps
- Simultaneous measurement of DNA, RNA, and protein from the same sample
- Ultra‑sensitive signal detection capable of quantifying low‑abundance proteins
- Physics‑based assay design that provides consistent performance across sample types
- Rapid turnaround time compared to conventional immunoassays and nucleic‑acid tests
- Compatibility with standard laboratory equipment and data analysis pipelines